Immunotherapy against amyloid pathology in Alzheimer's disease

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed "disease modifying" drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms, including the deposition of extracellular amyloid beta (Aβ) plaques and of intracellular neurofibrillary tangles. The most innovative approach is represented by the vaccination and passive immunization against Aβ peptide. In this article, current knowledge about concluded and ongoing clinical trials with both vaccination with different antigens and passive immunization will be reviewed and discussed.

Original languageEnglish
Pages (from-to)50-54
Number of pages5
JournalJournal of the Neurological Sciences
Volume333
Issue number1-2
DOIs
Publication statusPublished - Oct 15 2013

Fingerprint

Amyloid
Immunotherapy
Alzheimer Disease
Pathology
Passive Immunization
Cholinesterase Inhibitors
Vaccination
Pharmaceutical Preparations
Memantine
Neurofibrillary Tangles
Acetylcholine
Disease Progression
Therapeutics
Clinical Trials
Antigens
Peptides

Keywords

  • Alzheimer's disease
  • Amyloid
  • Disease-modifying drugs
  • Passive immunization
  • Vaccination

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Immunotherapy against amyloid pathology in Alzheimer's disease. / Galimberti, Daniela; Ghezzi, Laura; Scarpini, Elio.

In: Journal of the Neurological Sciences, Vol. 333, No. 1-2, 15.10.2013, p. 50-54.

Research output: Contribution to journalArticle

@article{ce4dd16876814a0e9fbcd14626324ec2,
title = "Immunotherapy against amyloid pathology in Alzheimer's disease",
abstract = "The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed {"}disease modifying{"} drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms, including the deposition of extracellular amyloid beta (Aβ) plaques and of intracellular neurofibrillary tangles. The most innovative approach is represented by the vaccination and passive immunization against Aβ peptide. In this article, current knowledge about concluded and ongoing clinical trials with both vaccination with different antigens and passive immunization will be reviewed and discussed.",
keywords = "Alzheimer's disease, Amyloid, Disease-modifying drugs, Passive immunization, Vaccination",
author = "Daniela Galimberti and Laura Ghezzi and Elio Scarpini",
year = "2013",
month = "10",
day = "15",
doi = "10.1016/j.jns.2012.12.013",
language = "English",
volume = "333",
pages = "50--54",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Immunotherapy against amyloid pathology in Alzheimer's disease

AU - Galimberti, Daniela

AU - Ghezzi, Laura

AU - Scarpini, Elio

PY - 2013/10/15

Y1 - 2013/10/15

N2 - The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed "disease modifying" drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms, including the deposition of extracellular amyloid beta (Aβ) plaques and of intracellular neurofibrillary tangles. The most innovative approach is represented by the vaccination and passive immunization against Aβ peptide. In this article, current knowledge about concluded and ongoing clinical trials with both vaccination with different antigens and passive immunization will be reviewed and discussed.

AB - The first drugs developed for Alzheimer's disease (AD), anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed "disease modifying" drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms, including the deposition of extracellular amyloid beta (Aβ) plaques and of intracellular neurofibrillary tangles. The most innovative approach is represented by the vaccination and passive immunization against Aβ peptide. In this article, current knowledge about concluded and ongoing clinical trials with both vaccination with different antigens and passive immunization will be reviewed and discussed.

KW - Alzheimer's disease

KW - Amyloid

KW - Disease-modifying drugs

KW - Passive immunization

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=84884910087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884910087&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2012.12.013

DO - 10.1016/j.jns.2012.12.013

M3 - Article

VL - 333

SP - 50

EP - 54

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -